Risk assessment in pulmonary arterial hypertension patients with multiple comorbidities and/or advanced age—Where do we stand and what's next?

Risk assessment in pulmonary arterial hypertension patients with multiple comorbidities and/or advanced age—Where do we stand and what's next?

Bibliographic Details
Main Authors:	Abdulla Ahmed, Salaheldin Ahmed, Göran Rådegran
Format:	Article
Language:	English
Published:	Wiley 2023-10-01
Series:	Pulmonary Circulation
Online Access:	https://doi.org/10.1002/pul2.12314

Similar Items

Structured evaluation of unclear dyspnea–An attempt to shorten the diagnostic delay in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: Salaheldin Ahmed, et al.
Published: (2024-01-01)

Risk assessment in pulmonary arterial hypertension: A step towards clinical implementation based on the 2022 ESC/ERS pulmonary hypertension guidelines
by: Abdulla Ahmed, et al.
Published: (2023-04-01)

Plasma TRAIL and ANXA1 in diagnosis and prognostication of pulmonary arterial hypertension
by: Mattias Arvidsson, et al.
Published: (2023-07-01)

Elevated plasma WIF‐1 levels are associated with worse prognosis in heart failure with pulmonary hypertension
by: Kriss Kania, et al.
Published: (2022-12-01)

Higher plasma IL-6 and PTX3 are associated with worse survival in left heart failure with pulmonary hypertension
by: Sara Helleberg, et al.
Published: (2022-08-01)

Plasma tumour necrosis factor‐alpha‐related proteins in prognosis of heart failure with pulmonary hypertension
by: Adam Engel Sällberg, et al.
Published: (2023-12-01)

Bio-inspired computation : where we stand and what’s next
by: Del Ser, Javier, et al.
Published: (2020)

Plasma matrix metalloproteinase 2 is associated with severity and mortality in pulmonary arterial hypertension
by: Mattias Arvidsson, et al.
Published: (2022-01-01)

Gene × Environment interaction in developmental disorders : where do we stand and what’s next?
by: Esposito, Gianluca, et al.
Published: (2019)

Plasma adrenomedullin peptides and precursor levels in pulmonary arterial hypertension disease severity and risk stratification
by: Habib Bouzina, et al.
Published: (2020-06-01)

The Evolution of Reverse Total Shoulder Arthroplasty—Where Do We Stand and What Comes Next?
by: Stefan Bauer, et al.
Published: (2023-03-01)

Moving Average-Based Multitasking In Silico Classification Modeling: Where Do We Stand and What Is Next?
by: Amit Kumar Halder, et al.
Published: (2022-04-01)

Everyday life experiences of spouses of patients who suffer from pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
by: Bodil Ivarsson, et al.
Published: (2019-02-01)

Low plasma stem cell factor combined with high transforming growth factor-α identifies high-risk patients in pulmonary arterial hypertension
by: Habib Bouzina, et al.
Published: (2018-11-01)

Genomics of Trypanosomatidae: Where We Stand and What Needs to Be Done?
by: Vyacheslav Yurchenko, et al.
Published: (2021-09-01)

Modeling Myxofibrosarcoma: Where Do We Stand and What Is Missing?
by: Enrico Lucarelli, et al.
Published: (2023-10-01)

Interventional treatment of pulmonary embolism - where do we currently stand?
by: G. Dobrev, et al.
Published: (2022-09-01)

Editorial: Neonatal and Pediatric Cerebro-Cardio-Pulmonary Resuscitation (CCPR): Where Do We Stand and Where Are We Heading?
by: Utpal Bhalala, et al.
Published: (2018-06-01)

To block the renin system or the calcium channel in hypertension — where do we stand?
by: Peter S Sever
Published: (2000-12-01)

Cervical cancer prevention in China: where are we now, and what’s next?
by: Huijiao Yan, et al.
Published: (2024-03-01)

Adrenomedullin peptides and precursor levels in relation to haemodynamics and prognosis after heart transplantation
by: Abdulla Ahmed, et al.
Published: (2023-08-01)

Where we do stand on integrity?
by: Abd Razak, Dzulkifli
Published: (2007)

Where are we standing in occupational cardiology?
by: Uğur Nadir Karakulak
Published: (2015-09-01)

Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
by: Chiara Villa
Published: (2020-11-01)

Sympathetic Modulation in Cardiac Arrhythmias: Where We Stand and Where We Go
by: Wei-Hsin Chung, et al.
Published: (2023-05-01)

Translating Tolerogenic Therapies to the Clinic - Where Do We Stand and What are the Barriers?
by: Cobbold, S, et al.
Published: (2012)

Artificial Intelligence in Senology - Where Do We Stand and What Are the Future Horizons?
by: Alexander Mundinger, et al.
Published: (2024-04-01)

Where we have been, where we are now, and where we might be heading : Where next for the coaching relationship?
by: Alanna O'Broin
Published: (2016-12-01)

Metformin and Vitamin B12 Deficiency: Where Do We Stand?
by: Marwan Awad Ahmed
Published: (2016-10-01)

Anti-Inflammatory Therapy in Coronary Artery Disease: Where Do We Stand?
by: Jelena Rakocevic, et al.
Published: (2023-01-01)

Ovarian cancer in the older patient: where are we now? What to do next?
by: Frédérique Rousseau, et al.
Published: (2023-09-01)

A Systematic Review of the Application of Artificial Intelligence in Nursing Care: Where are We, and What’s Next?
by: Ruksakulpiwat S, et al.
Published: (2024-04-01)

Late Sodium Current of the Heart: Where Do We Stand and Where Are We Going?
by: Balázs Horváth, et al.
Published: (2022-02-01)

The Role of Angiogenesis in Haemophilic Arthropathy: Where Do We Stand and Where Are We Going?
by: Alexandra Agapidou, et al.
Published: (2016-05-01)

Chronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?
by: Gemma E. Hayes, et al.
Published: (2016-06-01)

Transplantation tolerance-where do we stand?
by: Waldmann, H
Published: (1999)

Vaccine for Diabetes—Where Do We Stand?
by: Dinesh Kumar Chellappan, et al.
Published: (2022-08-01)

Knowledge of Anatomy: Where Do we Stand?
by: Muhammad Saeed, et al.
Published: (2009-12-01)

Microbiological surveillance – where do we stand?
by: Ulrike Beilenhoff
Published: (2023-04-01)

Knowledge of Anatomy: Where Do we Stand?
by: Muhammad Saeed, et al.
Published: (2009-12-01)